AEGR Profile
Aegerion Pharmaceuticals, Inc. (AEGR) was a biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company's primary product was Juxtapid (lomitapide), a treatment for homozygous familial hypercholesterolemia, a rare and life-threatening genetic disease that results in high levels of LDL cholesterol.
Juxtapid was approved by the FDA in 2012 and was the first FDA-approved treatment for homozygous familial hypercholesterolemia. The drug was a significant breakthrough in the treatment of this disease, and it was hailed as a major advance in the field of rare disease treatment.
However, Aegerion faced numerous challenges during its history, including regulatory investigations and legal issues related to its sales and marketing practices. In 2017, the company was acquired by Novelion Therapeutics, which subsequently changed its name to Amryt Pharma.
Today, Juxtapid is still available as a treatment for homozygous familial hypercholesterolemia, but it is now marketed and distributed by Amryt Pharma. Despite the challenges faced by Aegerion during its history, the development of Juxtapid was a significant achievement in the field of rare disease treatment, and it continues to provide a life-saving treatment option for patients with this rare disease.
|
